Novo Nordisk Collaborates With Omega Therapeutics And Cellarity For Obesity, Metabolic Dysfunction-associated Steatohepatitis, Respectively; Novo Nordisk Will Reimburse R&D Costs, Each Company And Flagship's Pioneering Medicines Will Receive Up To $532M
Author: Benzinga Newsdesk | January 04, 2024 07:09am
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering.
Novo Nordisk will reimburse R&D costs and each company and Flagship's Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties